Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05920577
Other study ID # Frailty_2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date December 30, 2024

Study information

Verified date April 2024
Source Hong Kong Metropolitan University
Contact Liu Tai Wa, PhD
Phone 00852 39708714
Email twliu@hkmu.edu.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. Sacropenia and impaired cognitive function are two major contributors to frailty. This study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.


Description:

Frailty is a common geriatric condition with significantly increased vulnerability to stress and susceptibility of negative health-related outcomes. The prevalence rates of frailty varies across countries, and the pooled estimates of prevalence rates of 52.3% and 40.2% of frailty and prefrailty were reported among nursing home residents respectively. Previous studies also revealed that frailty is predictive for various adverse health outcomes. Sacropenia is a major etiologic risk factor to frailty. It refers to an age-related generalised muscle disorder featuring with loss of muscle mass and function5. Talar et al systematically reviewed and meta-analysed 25 randomised controlled trials (RCTs) using resistance training among 2,267 older people (age >65 years) with pre-sarcopenia, sarcopenia, pre-frailty or frailty. It was revealed that, compared to control, resistance training with at least 8 weeks intervention period had small to large effects in improving handgrip strength, lower-limb strength, agility, gait speed, postural stability, functional performance, fat mass and muscle [Effect size (ES) = 0.29 - 0.93, p <0.001 to = 0.007]. Cognitive impairment is another major risk factor for declined frailty status among prefrail older people. Non-frail older people are known to have better performance on cognitive status, including processing speed, executive function, attention and working memory, immediate memory and delayed memory (g = 0.320 to 0.64), than frail older people. Ample research evidence suggested that cognition predicts the incidence of frailty. Exergaming is a fast growing research trend in gerontechnology and several commercial exergaming consoles, such as the Xbox system (including Xbox One and Xbox 360) and Nintendo Will (Wii Sports and Wii Fit), are available. Ogawa et al systematically reviewed 7 clinical trials (5 RCTs and 2 uncontrolled studies) and revealed that exergaming could improve cognitive functions, including executive function, process speed and reaction time, of older people. Moreover, a recent RCT revealed that, compared with the combined use of exercise (resistance, aerobic and balance training), a 12 week Kinect-based exergaming could better improve the global cognition [F(1, 44) = 5.277, p = 0.026] as measured by the Montreal Cognitive Assessment of community-frail older people. The Kinect-based group (n = 25) also demonstrated significant improvement in verbal (p < 0.05) and working (p < 0.05) memory post-intervention but the combined exercise group (n = 21) did not. Given that sacropenia and impaired cognitive function are 2 major contributors to frailty; and exergaming and resistance training are effective treatments in improving the cognitive function and sacropenia of older people respectively, this study aims to evaluate the effects of the combined use of exergaming and resistance training in improving the frailty of nursing home residents.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 60 Years to 90 Years
Eligibility Inclusion Criteria: - living in a nursing home - fulfilled 1, 2 or 3 Fried Criteria of frailty - score =7 of 10 on the Chinese version of the Abbreviated Mental Test - able to follow the instructions of assessment and intervention Exclusion Criteria: - involved in any drug or other clinical trials - having any additional medical conditions (such as epilepsy) - unable to walk independently without the use of walking aids - having any other conditions that will hinder the assessment and intervention (e.g.,visual/audio impairment could not be corrected by glasses/hearing aids etc).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
exergames and resistance training
In each session, the participants will receive 40 minutes of combined use of exergaming and resistance training. The participants will practice the exergames using the gaming system Nintendo Switch (Nintendo Co., Ltd, Kyoto, Japan). The gaming software "Nintendo Switch Sports" will be adopted in which arrays of exergames are available to strengthen both the upper and lower extremity muscle and improve the balance ability of participants. The exergaming programme will consist of both upper (badminton game and tennis game) and lower (soccer game) extremity games. For week 1 and 2, the participants will first practice 1-minute warm up exercise (stretching exercises) and then the 3 exergames. For week 3 to 12, the participants will receive the same warm up exercise and exergames as if week 1 and 2 but there will be an addition of light cuff weight for resistance training.
Resistance training
The resistance training programme consists of 2 parts, the upper limb and lower limb resistance exercises. For the upper limb resistance exercises, the participants will first practice 5-minute warm up of upper limb using ergometer and then undergo 2 resistance exercises, including handgrip and elbow flexion. For the lower limb exercise, the participants will also first practice 5-minute warm up of lower limb using ergometer and then undergo 3 resistance exercises, including squatting, single-leg standing and knee extension.

Locations

Country Name City State
Hong Kong Jockey club Institute of Health Ho Man Tin

Sponsors (1)

Lead Sponsor Collaborator
Hong Kong Metropolitan University

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Muscle quantity, higher score means better muscle quantity Will be assessed using a bioelectrical impedance measurement T1: baseline (before the study begins)
Primary Change from baseline muscle quantity at 6 weeks, higher score means better muscle quantity Will be assessed using a bioelectrical impedance measurement T2: mid-intervention (week 6)
Primary Change from baseline muscle quantity at 12 weeks, higher score means better muscle quantity Will be assessed using a bioelectrical impedance measurement T3: post-intervention (week 12)
Primary Change from baseline muscle quantity at 16 weeks, higher score means better muscle quantity Will be assssed using a bioelectrical impedance measurement T4: 1 month follow up (week 16)
Primary Change from baseline muscle quantity at 24 weeks, higher score means better muscle quantity Will be assssed using a bioelectrical impedance measurement T5: 3 months follow up (week 24)
Primary Muscle strength, higher score means better muscle strength Will be assessed using a handheld dynamometer T1: baseline (before the study begins)
Primary Change from baseline muscle strength at 6 weeks, higher score means better muscle strength Will be assessed using a handheld dynamometer T2: mid-intervention (week 6)
Primary Change from baseline muscle strength at 12 weeks, higher score means better muscle strength Will be assessed using a handheld dynamometer T3: post-intervention (week 12)
Primary Change from baseline muscle strength at 16 weeks, higher score means better muscle strength Will be assessed using a handheld dynamometer T4: 1 month follow up (week 16)
Primary Change from baseline muscle strength at 24 weeks, higher score means better muscle strength Will be assessed using a handheld dynamometer T5: 3 months follow up (week 24)
Primary Lower Extremity functions, score ranged from 0-12, higher scores mean better lower extremity functions Will be assessed using the Short Physical Performance Battery T1: baseline (before the study begins)
Primary Change from baseline lower extremity functions at 6 weeks, score ranged from 0-12, higher scores mean better lower extremity functions Will be assessed using the Short Physical Performance Battery T2: mid-intervention (week 6)
Primary Change from baseline lower extremity functions at 12 weeks, score ranged from 0-12, higher scores mean better lower extremity functions Will be assessed using the Short Physical Performance Battery T3: post-intervention (week 12)
Primary Change from baseline lower extremity functions at 16 weeks, score ranged from 0-12, higher scores mean better lower extremity functions Will be assessed using the Short Physical Performance Battery T4: 1 month follow up (week 16)
Primary Change from baseline lower extremity functions at 24 weeks, score ranged from 0-12, higher scores mean better lower extremity functions Will be assessed using the Short Physical Performance Battery T5: 3 months follow up (week 24)
Secondary Cognitive function, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition Will be assessed using the Montreal Cognitive Assessment (HK version) T1: baseline (before the study begins)
Secondary Change from baseline cognitive function at 6 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition Will be assessed using the Montreal Cognitive Assessment (HK version) T2: mid-intervention (week 6)
Secondary Change from baseline cognitive function at 12 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition Will be assessed using the Montreal Cognitive Assessment (HK version) T3: post-intervention (week 12)
Secondary Change from baseline cognitive function at 16 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition Will be assessed using the Montreal Cognitive Assessment (HK version) T4: 1 month follow up (week 16)
Secondary Change from baseline cognitive function at 24 weeks, higher score means better cognitive function, score ranged from 0 - 30, higher scores mean better cognition Will be assessed using the Montreal Cognitive Assessment (HK version) T5: 3 months follow up (week 24)
Secondary Mobility, longer time means worse functional mobility Will be assessed using the Timed Up and Go Test T1: baseline (before the study begins)
Secondary Change from baseline mobility at 6 weeks, longer time means worse functional mobility Will be assessed using the Timed Up and Go Test T2: mid-intervention (week 6)
Secondary Change from baseline mobility at 12 weeks, longer time means worse functional mobility Will be assessed using the Timed Up and Go Test T3: post-intervention (week 12)
Secondary Change from baseline mobility at 16 weeks, longer time means worse functional mobility Will be assessed using the Timed Up and Go Test T4: 1 month follow up (week 16)
Secondary Change from baseline mobility at 24 weeks, longer time means worse functional mobility Will be assessed using the Timed Up and Go Test T5: 3 months follow up (week 24)
Secondary Frailty, score range 0 to 9, higher score means higher level of frailty Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C) T1: baseline (before the study begins)
Secondary Change from baseline frailty at 6 weeks, score range 0 to 9, higher score means higher level of frailty Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C) T2: mid-intervention (week 6)
Secondary Change from baseline frailty at 12 weeks, score range 0 to 9, higher score means higher level of frailty Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C) T3: post-intervention (week 12)
Secondary Change from baseline frailty at 16 weeks, score range 0 to 9, higher score means higher level of frailty Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C) T4: 1 month follow up (week 16)
Secondary Change from baseline frailty at 24 weeks, score range 0 to 9, higher score means higher level of frailty Will be assessed using the Chinese version of Clinical Frailty Scale (CFS-C) T5: 3 months follow up (week 24)
Secondary Sarcopenia, score ranged from 0 to 20, lower score means lower risk Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf) T1: baseline (before the study begins)
Secondary Change from baseline sarcopenia at 6 weeks, score ranged from 0 to 20, lower score means lower risk Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf) T2: mid-intervention (week 6)
Secondary Change from baseline sarcopenia at 12 weeks, score ranged from 0 to 20, lower score means lower risk Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls(SARC-Calf) T3: post-intervention (week 12)
Secondary Change from baseline sarcopenia at 16 weeks, score ranged from 0 to 20, lower score means lower risk Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf) T4: 1 month follow up (week 16)
Secondary Change from baseline sarcopenia at 24 weeks, score ranged from 0 to 20, lower score means lower risk Will be assessed using the Strength, Assistance with walking, Rise from a chair, Climb stairs and (Calf) Falls (SARC-Calf) T5: 3 month follow up (week 16)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04992286 - Detection, Evaluation and Monitoring of Frailties in the Elderly (FRAGING) N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04061785 - Impact of Skills Acquired Through Judo Training on Risk Factors for Falling in Elderly Men and Women N/A
Completed NCT04140890 - Supporting Habit Formation to Attenuate Prefrailty in Elders: Pilot Study N/A
Recruiting NCT03141866 - Seated Physical Activity in Ageing N/A
Completed NCT04888884 - Loss of Independence - a Rapid Alternative to Frailty Screening in a Swedish ED Setting
Recruiting NCT04145726 - Frailty In Thoracic Surgery for Esophageal Cancer
Recruiting NCT04717869 - Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
Not yet recruiting NCT06022666 - PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery. N/A
Not yet recruiting NCT04514536 - Evaluation of a Health Monitoring Platform for Elderly in Home Care Context N/A
Completed NCT01126723 - Effects of Tai Chi on Frailty in Elderly Adults N/A
Completed NCT00183040 - HORMA: Hormonal Regulators of Muscle and Metabolism in Aging Phase 2
Active, not recruiting NCT05961319 - Smart Home Technologies for Assessing and Monitoring Frailty in Older Adults
Enrolling by invitation NCT05047731 - Antihypertensive Deprescribing in Long-term Care N/A
Completed NCT04956705 - Vitamin D and Calcium Supplementation at Danish Nursing Homes N/A
Recruiting NCT03824106 - Frailty Rehabilitation Phase 4
Recruiting NCT04518423 - Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People
Completed NCT04087343 - Strength on Wheels: A Meal Delivery and Exercise Intervention for Homebound Older Adults N/A